Table 6.
Current Clinical Trials Testing DDR Inhibitors in Glioma
| Target | Agent | Trial Name | Phase | Regimen | Tumor Type(s)/ Patient Populations | Status | PI/Co-PI | Trial ID(s) |
|---|---|---|---|---|---|---|---|---|
| PARP | Veliparib | A071102 (Alliance) | 2/3 | TMZ-/+Veliparib | Newly diagnosed GBM, Adults | Active, not recruiting | Sarkaria | NCT02152982 |
| Olaparib | OPARATIC | 1 | Olaparib and TMZ | Recurrent GBM, adults | Completed | Chalmers | - | |
| PARADIGM | 1/2 | Olaparib and RT | Newly diagnosed GBM, 65+ y | Recruiting (Phase II) | Chalmers | - | ||
| PARADIGM-2 | 1 | Olaparib and RT | Newly diagnosed GBM, Adults | Recruiting (MGMT- cohort) | Chalmers | - | ||
| ETCTN 10129 | 2 | Monotherapy | Recurrent IDH1/2-mutant glioma, adults | Recruiting | LoRusso/Bindra | NCT03212274 | ||
| BGB290 | Study 104 | 1/2 | BGB290 with RT and/or TMZ | Recurrent GBM, adults | Recruiting | Brachman | NCT03150862 | |
| ABTC-1801 | 1/2 | BGB290 with TMZ | Recurrent IDH1/2-mutant glioma, adults | Recruiting | Bindra/Schiff | NCT03914742 | ||
| PNOC017 | 1 | BGB290 with TMZ | Recurrent IDH1/2-mutant glioma, ages 13–25 y | Recruiting | Marks/Bindra | NCT03749187 | ||
| ATM | AZD1390 | AstraZeneca | 1 | AZD1390 and RT | Newly diagnosed and recurrent GBM, adults | Recruiting | Wen | NCT03423628 |
| DNA-PK | CC115 | INSIGhT | GBM | CC115 and GBM | Newly diagnosed GBM, adults | Completed | Wen/Alexander | NCT02977780 |
| Wee1 | AZD1775 | ABTC-1202 | GBM | AZD1775, TMZ and RT | Newly diagnosed and recurrent GBM, adults | Completed | Lee | NCT01849146 |
| AZD1775 | - | 0 | Monotherapy | Recurrent GBM, adults | Completed | Sanai | NCT02207010 |
Abbreviations: RT, Radiotherapy; TMZ, TMZ; GBM, Glioblastoma.